Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

It's "PT" for SCD!

Rafal Pawlinski1

  • 1UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL.

Blood
|October 10, 2015
PubMed
Summary
This summary is machine-generated.

Reducing prothrombin (PT) expression long-term improved outcomes in a sickle cell disease (SCD) mouse model. This approach lessened vascular inflammation, organ damage, and increased survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When sickle cell trait is not just trait: risk of VTE.

Hematology. American Society of Hematology. Education Program·2025
Same author

Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms.

Blood advances·2025
Same author

Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model.

Blood advances·2025
Same author

Hypertonicity and/or acidosis induce marked rheological changes under hypoxic conditions in sickle trait red blood cells.

British journal of haematology·2024
Same author

4D intravital imaging studies identify platelets as the predominant cellular procoagulant surface in a mouse hemostasis model.

Blood·2024
Same author

Biased agonism of protease-activated receptor-1 regulates thromboinflammation in murine sickle cell disease.

Blood advances·2024
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Area of Science:

  • Hematology
  • Vascular Biology
  • Disease Pathophysiology

Background:

  • Sickle cell disease (SCD) is a genetic blood disorder characterized by chronic inflammation and organ damage.
  • Prothrombin (PT) plays a crucial role in the coagulation cascade, and its dysregulation is implicated in SCD complications.

Purpose of the Study:

  • To investigate the therapeutic potential of long-term prothrombin (PT) expression reduction in a mouse model of sickle cell disease (SCD).

Main Methods:

  • Utilized a mouse model of sickle cell disease (SCD).
  • Implemented a strategy for long-term reduction of prothrombin (PT) expression.
  • Assessed vascular inflammation, organ damage, and survival rates.

Main Results:

Related Experiment Videos

  • Long-term reduction of prothrombin (PT) expression significantly diminished vascular inflammation.
  • Observed attenuation of multiple organ damage in treated SCD mice.
  • Demonstrated a survival advantage in mice with reduced PT expression.

    • Conclusions:

    • Targeting prothrombin (PT) expression offers a promising therapeutic strategy for mitigating SCD complications.
    • Reduced PT expression ameliorates key pathological features of sickle cell disease (SCD), including inflammation and organ damage.